BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27329723)

  • 1. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
    Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
    Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SATB1 in Malignant T Cells.
    Fredholm S; Willerslev-Olsen A; Met Ö; Kubat L; Gluud M; Mathiasen SL; Friese C; Blümel E; Petersen DL; Hu T; Nastasi C; Lindahl LM; Buus TB; Krejsgaard T; Wasik MA; Kopp KL; Koralov SB; Persson JL; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Becker JC; Ødum N
    J Invest Dermatol; 2018 Aug; 138(8):1805-1815. PubMed ID: 29751003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
    Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
    Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA in mycosis fungoides and skin inflammation.
    Persson JL
    APMIS; 2013 Nov; 121(11):1017-9. PubMed ID: 24106870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Nielsen BS; Gniadecki R; Woetmann A; Ødum N; Ralfkiaer E
    APMIS; 2013 Nov; 121(11):1020-4. PubMed ID: 24033365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
    Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
    Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
    Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
    J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.
    Zhang Q; Wang HY; Wei F; Liu X; Paterson JC; Roy D; Mihova D; Woetmann A; Ptasznik A; Odum N; Schuster SJ; Marafioti T; Riley JL; Wasik MA
    J Immunol; 2014 Mar; 192(6):2913-9. PubMed ID: 24523507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
    Willerslev-Olsen A; Litvinov IV; Fredholm SM; Petersen DL; Sibbesen NA; Gniadecki R; Zhang Q; Bonefeld CM; Wasik MA; Geisler C; Zhou Y; Woetmann A; Sasseville D; Krejsgaard T; Odum N
    Cell Cycle; 2014; 13(8):1306-12. PubMed ID: 24621498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.